High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 693-702

  Pierantoni, Giovanna Maria ^a   Rinaldo, Cinzia ^b   Mottolese, Marcella ^b   Benedetto, Anna Di ^b   Esposito, Francesco ^a   Soddu, Silvia ^b   Fusco, Alfredo ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A PROTEIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CYTOPLASM; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; CARRIER PROTEINS; CELL NUCLEUS; CYTOPLASM; GENE EXPRESSION REGULATION; HMGA1A PROTEIN; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847398755     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29852     Document Type: Article

References (50)

1. Grosschedl, R., Giese, K., and Pagel, J. 1994. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet. 10:94-100.
2. Reeves, R., and Nissen, M.S. 1990. The A-T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 265:8573-8582.
3. Reeves, R. 2000. Structure and function of the HMGI(Y) family of architectural transcription factors. Environ. Health Perspect. 108:803-809.
4. Thanos, D., and Maniatis, T. 1995. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell. 83:1091-1100.
5. Zhou, X., Benson, K.F., Ashar, H.R., and Chada, K. 1995. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature. 376:771-774.
6. Chiappetta, G., et al. 1996. High level expression of the HMGA1 gene during embryonic development. Oncogene. 13:2439-2446.
7. Chiappetta, G., et al. 1995. The expression of the high mobility group HMGA1 proteins correlates with the malignant phenotype of human thyroid neoplasms. Oncogene. 10:1307-1314.
8. Chiappetta, G., et al. 1998. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. 58:4193-4198.
9. Fedele, M., et al. 1996. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res. 56:1896-1901.
10. Abe, N., et al. 1999. Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res. 59:1169-1174.
11. Chiappetta, G., et al. 2001. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int. J. Cancer. 91:147-151.
12. Tamimi, Y., et al. 1993. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res. 53:5512-5516.
13. Abe, N., et al. 2002. Diagnostic significance of high mobility group I(Y) protein expression in intraductal papillary mucinous tumors of the pancreas. Pancreas. 25:198-204.
14. Bandiera, A., et al. 1998. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res. 58:426-431.
15. Masciullo, V., et al. 2003. HMGA1 protein overexpression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis. 24:1191-1198.
16. Chiappetta, G., et al. 2004. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin. Cancer Res. 10:7637-7644.
17. Berlingieri, M.T., et al. 1995. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell. Biol. 15:1545-1553.
18. Berlingieri, M.T., Pierantoni, G.M., Giancotti, V., Santoro, M., and Fusco, A. 2002. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene. 21:2971-2980.
19. Scala, S., Portella, G., Fedele, M., Chiappetta, G., and Fusco, A. 2000. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl. Acad. Sci. U. S. A. 97:4256-4261.
20. Pierantoni, G.M., et al. 2006. High Mobility Group A1 (HMGA1) proteins interact with p53 and interfere with its apoptotic function. Cell Death Differ. 13:1554-1563.
21. Vousden, K.H. 2000. p53: death star. Cell. 103:691-694.
22. Vogelstein, B., Lane, D., and Levine, A.J. 2000. Surfing the p53 network. Nature. 408:307-310.
23. Schmitt, C.A., et al. 2002. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 1:289-296.
24. Appella, E., and Anderson, C.W. 2000. Signaling to p53: breaking the post-translational modification code. Pathol. Biol. 48:227-245.
25. Meek, J. 2004. The p53 response to DNA damage. DNA Repair. 3:1049-1056.
26. Bulavin, D.V., et al. 1999. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18:6845-6854.
27. Oda, K., et al. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:849-862.
28. Mayo, L.D., et al. 2005. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J. Biol. Chem. 280:25953-25959.
29. D'Orazi, G., et al. 2002. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4:11-19.
30. Hofmann, T.G., et al. 2002. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4:1-10.
31. Kim, E.-J., Park, J.-S., and Um, S.-J. 2002. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J. Biol. Chem. 277:32020-32028.
32. Zhang, Q., Yoshimatsu, Y., Hildebrand, J., Frisch, S.M., and Goodman, R.H. 2003. Homeodomain interacting protein kinase 2 promotes apoptosis by down-regulating the transcriptional co-repressor CtBP. Cell. 115:177-186.
33. Wang, Y., Debatin, K.M., and Hug, H. 2001. HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels. BMC Mol. Biol. 2:8-16.
34. Rui, Y., et al. 2004. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J. 23:4583-4594.
35. Pierantoni, G.M., et al. 2001. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene. 20:6132-6141.
36. Di Stefano, V., Rinaldo, C., Sacchi, A., Soddu, S., and D'Orazi, G. 2004. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp. Cell Res. 293:311-320.
37. Di Stefano, V., Soddu, S., Sacchi, A., and D'Orazi, G. 2005. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21(Waf1) after nonapoptotic DNA damage. Oncogene. 24:5431-5442.
38. Fukuda, M., et al. 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:308-311.
39. Moller, A., et al. 2003. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 63:4310-4314.
40. Mottolese, M., et al. 2007. Bio-pathologic characteristics according to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: identification of an adverse prognostic profile. Am. J. Surg. Pathol. In press.
41. Frasca, F., et al. 2006. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res. 66:2980-2989.
42. Cecchinelli, B., et al. 2006. Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ. 13:1994-1997.
43. Cecchinelli, B., et al. 2006. Repression of the antiapoptotic molecule galectin-3 by HIPK2-activated p53 is required for p53-induced apoptosis. Mol. Cell. Biol. 26:4746-4757.
44. Gostissa, M., Hofmann, T.G., Will, H., and Del Sal, G. 2003. Regulation of p53 functions: let's meet at the nuclear bodies. Curr. Opin. Cell Biol. 15:351-357.
45. Ostermeyer, A.G., Runko, E., Winkfield, B., Ahn, B., and Moll, U.M. 1996. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc. Natl. Acad. Sci. U. S. A. 93:15190-15194.
46. Lu, W., et al. 2000. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene. 19:232-240.
47. Schreiber, E., Matthias, P., Muller, M.M., and Schaffner, W. 1989. Rapid detection of octamer binding proteins with mini-extracts, prepared from a small number of cells. Nucleic Acid Res. 17:6419-6420.
48. Frontini, M., Imbriano, C., Manni, I., and Mantovani, R. 2004. Cell cycle regulation of NF-YC nuclear localization. Cell Cycle. 3:217-222.
49. Bacchetti, S., and Graham, F. 1993. Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein. Int. J. Oncol. 3:781-788.
50. International Union Against Cancer. 2002. TNM classification of malignant tumors. L.H. Sobin and Ch. Witteking, editors. Wilery-Liss. New York, New York, USA. 272 pp.